Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.
about
Recent advances in metabolic and bariatric surgeryMicrobial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventionsProbiotics as Complementary Treatment for Metabolic DisordersThe gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseasesGut Microbiome and Obesity: A Plausible Explanation for ObesityA genome-wide screen of bacterial mutants that enhance dauer formation in C. elegansThe effect of oxidized phospholipids on phenotypic polarization and function of macrophages.The gut microbiome in cardio-metabolic health.The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities.Recent advances in microbial fermentation for dairy and healthBugs, guts and brains, and the regulation of food intake and body weightGut microbiota: a key player in health and disease. A review focused on obesity.Impacts of gut bacteria on human health and diseases.Probiotics in obstetrics and gynaecology.Circadian metabolism in the light of evolutionLayering genetic circuits to build a single cell, bacterial half adderIsolevuglandin-type lipid aldehydes induce the inflammatory response of macrophages by modifying phosphatidylethanolamines and activating the receptor for advanced glycation endproducts.Endocannabinoids--at the crossroads between the gut microbiota and host metabolism.The Host Shapes the Gut Microbiota via Fecal MicroRNAGut microbiome as a novel cardiovascular therapeutic target.Manipulating Bacterial Communities by in situ Microbiome Engineering.The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development.IMNGS: A comprehensive open resource of processed 16S rRNA microbial profiles for ecology and diversity studies.Genetically Engineered Escherichia coli Nissle 1917 Synbiotics Reduce Metabolic Effects Induced by Chronic Consumption of Dietary FructoseWhole genome sequence analysis of the TALLYHO/Jng mouse.Gut Microbiota in Cardiovascular Health and Disease.Programming a Human Commensal Bacterium, Bacteroides thetaiotaomicron, to Sense and Respond to Stimuli in the Murine Gut MicrobiotaNew perspectives on the development of antiobesity drugs.Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease.Commensal bacteria make GPCR ligands that mimic human signalling molecules.Bioengineered probiotics as a new hope for health and diseases: an overview of potential and prospects.Microbiome therapeutics - Advances and challenges.Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health.Microbiome, probiotics and neurodegenerative diseases: deciphering the gut brain axis.Sustainable therapies by engineered bacteria.Environmental Pollutant Benzo[a]Pyrene Impacts the Volatile Metabolome and Transcriptome of the Human Gut MicrobiotaChronic Sleep Disruption Alters Gut Microbiota, Induces Systemic and Adipose Tissue Inflammation and Insulin Resistance in Mice.Cross sectional evaluation of the gut-microbiome metabolome axis in an Italian cohort of IBD patients.Dietary Capsaicin Improves Glucose Homeostasis and Alters the Gut Microbiota in Obese Diabetic ob/ob Mice.Recombinant Incretin-Secreting Microbe Improves Metabolic Dysfunction in High-Fat Diet Fed Rodents.
P2860
Q26745203-46405392-4B68-410E-A6E3-4F1893B0CDDFQ26751203-7ED04E8A-5889-4493-AB92-29730E5B5C35Q26795371-44A0C7CD-EA4B-472A-92E1-524CB3D21160Q27021692-165C5CE6-8E52-4370-B00C-E207A3CF493DQ28087145-99E85EDC-DB69-4DD0-B0D4-309965FF7504Q28817531-C3D6829F-E28E-46EB-9C0B-DD1C9F062127Q30268532-E42A2260-5DF1-4DD3-8F40-BE726D2C57BBQ30373247-43323710-C815-4D57-A0F2-18A6CFFABEE4Q33653853-B74B7AC4-679A-4C5B-9BF4-332D828FB96AQ33777826-17B8917B-3B2A-4323-9B1C-394A9C6BA721Q33838142-A4AE1B21-235A-404F-95FF-97F012D0A26FQ35573445-C4FFD9CF-45FF-4203-906C-92CE1F6FD6E3Q35585510-6845A5CC-7B71-45ED-B46F-B474ACCBF26CQ35656116-0C6E7691-69AC-4ECC-B7D6-81614EB4F34EQ35657123-5E2FDEAE-BD15-4975-A796-5DAA1D7DE1B6Q35664673-7E6906A8-5E96-45BE-806B-3EEB587A3743Q35797182-54C88425-3D12-49B2-9885-F2E64DE692CCQ35871872-02F3D68F-E389-4603-8310-C6160058DD39Q35893557-09FF8BCE-E263-456B-924F-4F3311E8FAC3Q35909450-DD6C6045-CF26-43C0-80D2-9793B4F98B7FQ35936180-07B6EE01-6CD5-4299-A776-6E97E15D1F7FQ35953201-806B7FB6-2B2B-46ED-9E15-474F6655F536Q36142070-4280CB70-9688-44D5-BBD8-AC4731FF8709Q36167895-E7DE57D0-9C90-48C6-B1FF-A4538E5E9474Q36190115-7F3E3D29-C3E3-44D1-A086-3EBC9A730538Q36329055-D64387AC-D1DB-4BF3-87AF-2D3A6AF9FD7BQ36602759-B06B710E-9AC5-4033-83A5-DCA7D050B032Q38397340-9A88ED8F-4F1E-4FBB-9728-7BAA22EBC455Q38497812-0E4F20E3-8A80-4EF2-9C7F-B323CF0407D7Q38635610-2B4B6085-902D-4EA3-AE8C-7F33FE4A090DQ38806283-64251EBB-EA4C-4B39-BE5B-8A141751DAE2Q38829360-AA1E64E6-F211-4A80-97A0-BF632AB69349Q39042753-760B4C54-E907-4603-8DC2-A15219369157Q39393210-F2399F93-4BB7-4943-A0B6-4D806D8DB375Q40140126-8519EDE0-211A-40B7-920B-57987DA42F32Q41436269-1E4439A6-07DD-4740-B961-75E55D5C521AQ41462254-8C0A9E89-2583-4C6B-80FC-F7A0EBE6C489Q41534067-DF32CE25-0AF6-4ACB-9852-AC5D344407AEQ41549135-A11B6014-13F5-4F05-A135-F7584345D26FQ42659870-87DB4C25-481F-48DF-9C08-7984F389658B
P2860
Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.
@ast
Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.
@en
type
label
Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.
@ast
Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.
@en
prefLabel
Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.
@ast
Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.
@en
P2093
P2860
P356
P1476
Incorporation of therapeutically modified bacteria into gut microbiota inhibits obesity.
@en
P2093
Denis Coulon
Elena Matafonova
Julie S Pendergast
Kevin D Niswender
Lindsey C Morris
Owen P McGuinness
Richard L Printz
Rosemary L Walzem
P2860
P304
P356
10.1172/JCI72517
P407
P577
2014-06-24T00:00:00Z